TONIX PHARMACEUTICALS HOLDING CORP. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $14.97 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-10
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $15.32, a 75.89% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $8.71, a 2077.50% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.40, a 48.05% decline year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.77, a 67.39% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $14.09, a 98.65% decline from fiscal 2024.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1042.00, a 92.94% decline from fiscal 2023.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $14763.00, a 21784.08% increase from fiscal 2022.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $67.46, a 65.14% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $14.97 10-Q · filed 2026-08-10 | ||||
| 2026-03-31 | $15.32 10-Q · filed 2026-05-11 | ||||
| 2025-12-31 | $14.09 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $13.79 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | $13.76 10-Q · filed 2025-08-11 | ||||
| 2025-03-31 | $8.71 10-Q · filed 2025-05-12 | ||||
| 2024-12-31 | $1042.00 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $10.30 10-Q · filed 2024-11-12 | ||||
| 2024-06-30 | $12.19 10-Q · filed 2024-08-16 | ||||
| 2024-03-31 | $0.40 10-Q · filed 2024-05-13 | ||||
| 2023-12-31 | $14763.00 10-K · filed 2025-03-18 | $4.64 10-K · filed 2024-04-01 | |||
| 2023-09-30 | $4.64 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $4.66 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | $0.77 10-Q · filed 2023-05-08 | ||||
| 2022-12-31 | $67.46 10-K · filed 2024-04-01 | $12.06 10-K · filed 2023-03-13 | |||
| 2022-09-30 | $12.06 10-Q · filed 2022-11-07 | ||||
| 2022-06-30 | $12.06 10-Q · filed 2022-08-08 | ||||
| 2022-03-31 | $0.46 10-Q · filed 2022-05-09 | ||||
| 2021-12-31 | $40.85 10-K · filed 2023-03-13 | $1.28 10-K · filed 2022-03-14 | |||
| 2021-09-30 | $1.28 10-Q · filed 2021-11-08 | ||||
| 2021-06-30 | $1.31 10-Q · filed 2021-08-09 | ||||
| 2021-03-31 | $1.34 10-Q · filed 2021-05-10 | ||||
| 2020-12-31 | $0.81 10-K · filed 2022-03-14 | ||||
| 2020-09-30 | $0.81 10-Q · filed 2020-11-09 | ||||
| 2020-06-30 | $0.81 10-Q · filed 2020-08-10 | ||||
| 2020-03-31 | $0.44 10-Q · filed 2020-05-12 | ||||
| 2019-12-31 | $21.74 10-K · filed 2021-03-15 | ||||
| 2019-09-30 | $21.74 10-Q · filed 2019-11-08 | ||||
| 2019-06-30 | $2.17 10-Q · filed 2019-08-12 | ||||
| 2019-03-31 | $2.06 10-Q · filed 2019-05-13 | ||||
| 2018-12-31 | $375.15 10-K · filed 2020-03-24 | $37.52 10-K · filed 2019-03-18 | |||
| 2018-09-30 | $3.75 10-Q · filed 2018-11-09 | ||||
| 2018-06-30 | $3.79 10-Q · filed 2018-08-13 | ||||
| 2018-03-31 | $3.70 10-Q · filed 2018-05-11 | ||||
| 2017-12-31 | $46.34 10-K · filed 2019-03-18 | $4.63 10-K · filed 2018-03-09 | |||
| 2017-09-30 | $4.63 10-Q · filed 2017-11-06 | ||||
| 2017-06-30 | $4.67 10-Q · filed 2017-08-11 | ||||
| 2017-03-31 | $5.50 10-Q · filed 2017-05-12 | ||||
| 2016-12-31 | $46.58 10-K · filed 2018-03-09 | ||||
| 2016-09-30 | $4.67 10-Q · filed 2016-11-10 | ||||
| 2016-06-30 | $4.67 10-Q · filed 2016-08-05 | ||||
| 2015-12-31 | $60.13 10-K · filed 2017-04-13 | $4.74 10-K · filed 2016-03-03 | |||
| 2014-12-31 | $8.20 10-K · filed 2016-03-03 | $9.53 10-K · filed 2015-02-27 | |||
| 2013-12-31 | $7.83 10-K · filed 2016-03-03 | $10.20 10-K · filed 2014-03-28 | |||
| 2012-12-31 | $30.00 10-K · filed 2014-03-28 | $1.50 10-K · filed 2013-03-11 | |||
| 2012-09-30 | $1.50 10-Q · filed 2012-11-14 | ||||
| 2012-06-30 | $1.50 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |